FierceBiotechOriginal article
{"a":[{"_":"AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda","$":{"href":"/biotech/astrazeneca-ends-phase-3-lung-cancer-trial-after-bispecific-falls-short-versus-keytruda","hreflang":"en"}}]}
Phase 3negativevolrustomigKeytrudaNegative
AI Analysis
Summary
AstraZeneca has terminated a phase 3 trial of volrustomig in lung cancer after interim efficacy data showed the bispecific fell short compared to Keytruda. The failure narrows the competitive opportunity for the drug in the immunotherapy space.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Trial stopped based on interim efficacy data showing bispecific fell short versus Keytruda
Importance:7/10
Sentiment:
-0.80
phase 3 failurelung cancerbispecific antibodytrial terminationimmunotherapy
Related Companies
Read the original article
Published by FierceBiotech on August 17, 2026 4:01 AM